DOCSLIB.ORG

Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke a Randomized Controlled Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Original Contributions Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke A Randomized Controlled Trial The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators Context.—Anticoagulation with unfractionated heparin is used commonly for ANTICOAGULATION with unfrac- treatment of acute ischemic stroke, but its use remains controversial because it has tionated heparin commonly is used to not been shown to be effective or safe. Low molecular weight heparins and hepa- treat persons with acute ischemic 1 rinoids have been shown to be effective in preventing deep vein thrombosis in per- stroke. However, the use of heparin re- mains controversial because it is not es- sons with stroke, and they might be effective in reducing unfavorable outcomes fol- 2-6 lowing ischemic stroke. tablished as safe or effective. A recent open trial demonstrated a modest effect Objective.—To test whether an intravenously administered low molecular from subcutaneously administered hep- weight heparinoid, ORG 10172 (danaparoid sodium), increases the likelihood of a arin in preventing recurrent stroke favorable outcome at 3 months after acute ischemic stroke. within 14 days but no improvement in Design.—Randomized, double-blind, placebo-controlled, multicenter trial. outcomes.7 Thus, whether an intrave- Setting and Participants.—Between December 22, 1990, and December 6, nously administered anticoagulant that 1997, 1281 persons with acute stroke were enrolled at 36 centers across the United would act more rapidly would be effec- States. tiveremainsunanswered.Thesearchfor Intervention.—A 7-day course of ORG 10172 or placebo was given initially as alternative medications that possess the a bolus within 24 hours of stroke, followed by continuous infusion in addition to the antithrombotic characteristics of hepa- best medical care. Doses were adjusted in response to anti–factor Xa activity. rin but have a lower propensity for bleeding or thrombocytopenia led to the Main Outcome Measures.—Favorable outcome rated as the combination of a development of low molecular weight Glasgow Outcome Scale score of I or II and a modified Barthel Index of 12 or greater heparins and heparinoids. A clinical trial on a scale of 0 to 20 at 3 months or 7 days; very favorable outcome was recorded recently showed a lower rate of unfavor- for the combination of a Glasgow Outcome Scale of I and a Barthel Index of 19 or able outcomes at 6 months after stroke 20 at 3 months or 7 days. following the administration of the low Results.—At 3 months, 482 (75.2%) of 641 persons assigned to treatment with molecular weight heparin, nadroparin, ORG 10172 and 467 (73.7%) of 634 patients treated with placebo had favorable butnosignificantdifferenceswerenoted outcomes (P=.49); 49.5% and 47%, respectively, of patients in each group had very at 10 days or 3 months.8 favorable outcomes at 3 months. At 7 days, 376 (59.2%) of 635 persons given ORG ORG 10172 (danaparoid sodium [Or- 10172 and 344 (54.3%) of 633 receiving placebo had favorable outcomes (P=.07). garan]) is a mixture of glycosaminogly- cans with a mean molecular weight of For the same interval, 215 (33.9%) of 635 persons given ORG 10172 and 176 5500 d that is isolated from porcine in- (27.8%) of 633 persons administered placebo had very favorable outcomes (P=.01; testinal mucosa. The anti–factor Xa ac- odds ratio, 1.36; 95% confidence interval, 1.06-1.73). Within 10 days of onset of tivity of ORG 10172 is attributed to its treatment, serious intracranial bleeding events occurred in 14 patients given ORG heparan sulfate component,9 which has a 10172 (15 events) and in 4 placebo-treated patients (5 events) (P=.05). high affinity for antithrombin III. It is Conclusion.—Despite an apparent positive response to treatment at 7 days, not inactivated by endogenous heparin- emergent administration of the antithrombotic agent, ORG 10172, is not associated neutralizing factors such as histidine- with an improvement in favorable outcome at 3 months. richglycoproteinorplateletfactor4,and JAMA. 1998;279:1265-1272 it has virtually no effect on platelet func- tion. It has minimal effects on the acti- vated partial thromboplastin time, pro- thrombin time, or thrombin time.10 The From the Publications Committee for the Trial of ence, Amsterdam, the Netherlands, May 29, 1997, and ORG 10172 in Acute Stroke Treatment (TOAST) In- at the 23rd International Joint Conference on Stroke and drug has low cross-reactivity to antibod- vestigators. Cerebral Circulation, Orlando, Fla, February 7, 1998. ies correlated with heparin-induced A complete list of the local principal investigators and Reprints: Harold P. Adams, Jr, MD, Division of Cere- thrombocytopenia, and it is used to treat coordinators and members of study committees ap- brovascular Diseases, Department of Neurology, Uni- pears at the end of this article. versity of Iowa College of Medicine, 200 Hawkins Dr, persons at high risk for thrombosis Presented in part at the Sixth European Stroke Confer- Iowa City, IA 52252 (e-mail: [email protected]). who have a history of heparin-induced JAMA, April 22/29, 1998—Vol 279, No. 16 ORG 10172 (Danaparoid) and Acute Ischemic Stroke—TOAST Investigators 1265 ©1998 American Medical Association. All rights reserved. Downloaded From: http://jama.jamanetwork.com/ by a Johns Hopkins University User on 07/02/2012 The primary outcome was a favorable Patients Screened outcome at 3 months after stroke, de- n=25 624 fined as a score of I or II on the Glasgow Ineligible Patients Outcome Scale and a score of 12 to 20 on n=23 720 17-19 Eligible Patients the modified Barthel Index. The in- n=1904 tention-to-treat (ITT) analysis required Consent Not Obtained that the patient have at least 1 postbase- n=623 Enrolled Patients line assessment of the Glasgow Outcome n=1281 Scale and Barthel Index. The study was designed to detect an improvement of ORG 10172 Placebo 20% with treatment (from an assumed n=646 n=635 base rate of 50%) with 90% power. Safety Analyses Safety Analyses Prespecified secondary hypotheses ITT Analyses n=638 ITT Analyses n=628 included a favorable outcome at 7 days, n=641 n=634 reducing recurrent stroke within 7 days, Premature Termination Premature Termination halting worsening of neurologic deficits of Study Drug of Study Drug within 7 days, and reducing mortality at n=94 n=87 7 days and 3 months. After a trial of thrombolytic therapy demonstrated a Follow-up at 3 Months Follow-up at 3 Months benefit in improving very favorable out- 20 Alive, Agreed to Follow-up n=591 Alive, Agreed to Follow-up n=583 comes after stroke, the TOAST inves- Dead n=44 Dead n=38 tigators added analyses evaluating simi- Alive, Refused Follow-up Visit n=7 Alive, Refused Follow-up Visit n=8 lar responses (defined as a combination Alive, Lost to Study n=2 Alive, Lost to Study n=1 of a Glasgow Outcome Scale score of I Lost to Study, Unknown Status n=2 Lost to Study, Unknown Status n=5 and a Barthel Index score of 19 or 20) at 7 days and 3 months. Neurologic wors- ening was assessed by evaluating differ- The populations were reported in TOAST (Trial of ORG 10172 [(danaparoid sodium, low molecular weight heparinoid] in Acute Stroke Treatment). The ITT (intention-to-treat) data were collected from persons who ences between the day 7 and baseline had at least 1 postbaseline outcome assessment. Postbaseline primary efficacy (Glasgow Outcome Scale scores of the NIHSS.21 Patients whose and Barthel Index scores) data were not provided by 5 patients assigned to treatment with ORG 10172 and day 7 NIHSS score was 4 or more points 1 patient treated with the placebo. These 6 patients were excluded from the ITT analysis. The safety analy- less than baseline or was 0 were classi- ses involve data collected from persons who received any amount of the study drug or placebo. fied as improved, a score that was within thrombocytopenia.11 It is also used for a stroke less than 24 hours old even with 3 points of baseline was considered un- prophylaxis against deep vein thrombo- recent progression, coma, mass effect changed, and a score of 4 or more addi- sis.12 Pilot studies examined the safety (shift of midline structures) on baseline tional points or death was rated as andpotentialutilityofORG10172inper- computed tomogram (CT), intracranial worse. sons with acute ischemic stroke.13,14 blood on a CT, CT evidence of a nonvas- Subtypes of acute ischemic stroke Based on the results of these projects, cular cause of symptoms, active bleed- were also a prespecified end point. Clas- the Trial of ORG 10172 in Acute Stroke ing, major surgery in the previous 24 sification was based on a central-blinded Treatment (TOAST) was performed to hours, another illness that required an- evaluationassessingtheclinicalfindings test the efficacy of the drug in improving ticoagulation, were currently receiving and the results of brain imaging and an- outcomes among persons with acute is- heparin or warfarin, received thrombo- cillary diagnostic tests, such as carotid chemic stroke. lytic therapy in the previous 24 hours, duplex or echocardiography. Categories active bleeding, abnormal baseline co- were large-artery atherosclerosis, car- METHODS agulation studies, mean blood pressure dioembolism, small-artery occlusion, other determined cause, or undeter- Design greater than 130 mm Hg, major organ 22 failure, known vasculitis or infective en- mined cause. TOAST was a randomized, double- docarditis, a complex medical illness or Safety analyses assessed events ex- blind, placebo-controlled multicenter terminal illness, confounding neurologic perienced by any treated patient subcat- trial conducted from December 1990 to disease, allergy to heparin, prior partici- egorized by the time of onset and in- December 1996 that treated persons pation in TOAST, or were participating cluded adverse experiences that occurred within 24 hours of the onset of acute is- in another clinical trial.
Recommended publications
  • Surfen, a Small Molecule Antagonist of Heparan Sulfate

    Surfen, a Small Molecule Antagonist of Heparan Sulfate

    Surfen, a small molecule antagonist of heparan sulfate Manuela Schuksz*†, Mark M. Fuster‡, Jillian R. Brown§, Brett E. Crawford§, David P. Ditto¶, Roger Lawrence*, Charles A. Glass§, Lianchun Wang*, Yitzhak Torʈ, and Jeffrey D. Esko*,** *Department of Cellular and Molecular Medicine, Glycobiology Research and Training Center, †Biomedical Sciences Graduate Program, ‡Department of Medicine, Division of Pulmonary and Critical Care Medicine and Veteran’s Administration San Diego Medical Center, ¶Moores Cancer Center, and ʈDepartment of Chemistry and Biochemistry, University of California at San Diego, La Jolla, CA 92093; and §Zacharon Pharmaceuticals, Inc, 505 Coast Blvd, South, La Jolla, CA 92037 Communicated by Carolyn R. Bertozzi, University of California, Berkeley, CA, June 18, 2008 (received for review May 26, 2007) In a search for small molecule antagonists of heparan sulfate, Surfen (bis-2-methyl-4-amino-quinolyl-6-carbamide) was first we examined the activity of bis-2-methyl-4-amino-quinolyl-6- described in 1938 as an excipient for the production of depot carbamide, also known as surfen. Fluorescence-based titrations insulin (16). Subsequent studies have shown that surfen can indicated that surfen bound to glycosaminoglycans, and the extent block C5a receptor binding (17) and lethal factor (LF) produced of binding increased according to charge density in the order by anthrax (18). It was also reported to have modest heparin- heparin > dermatan sulfate > heparan sulfate > chondroitin neutralizing effects in an oral feeding experiments in rats (19), sulfate. All charged groups in heparin (N-sulfates, O-sulfates, and but to our knowledge, no further studies involving heparin have carboxyl groups) contributed to binding, consistent with the idea been conducted, and its effects on HS are completely unknown.
  • A 74-Year-Old Woman with Abdominal Pain and Fever

    A 74-Year-Old Woman with Abdominal Pain and Fever

    A SELF-TEST IM BOARD REVIEW DAVID L. LONGWORTH, MO, JAMES K. STOLLER, MD, EDITORS OF CLINICAL PETER MAZZONE, MD CRAIG NIELSEN, MD RECOGNITION Department of Pulmonary and Critical Department of General Internal Care Medicine, Cleveland Clinic Medicine, Cleveland Clinic A 74-year-old woman with abdominal pain and fever 74-YEAR-OLD WOMAN was transferred pulmonary embolism, and a subsequent pul- from a local hospital for further evalua- monary angiogram was read as normal. A tion and management of abdominal pain with chest CT scan did not reveal anything other fever. than the small bilateral pleural effusions seen The patient had presented to the local on the chest radiograph. A thoracentesis hospital 11 days before with a 1-day history of revealed transudative fluid only. Intravenous bilateral upper-quadrant abdominal pain. She heparin was discontinued. described the pain as a constant ache with Past history. The patient had had essen- intermittent sharper pains accompanied by tial thrombocythemia for 5 years, for which nausea, but she could not identify any precip- she took hydroxyurea until 2 months before itants of the pain. She was also constipated. admission. Hydroxyurea was restarted at the A few days after being admitted to the local hospital because her platelet count was local hospital, the patient had developed a high at 750 x 109/L (normal 150-400 x fever and mild shortness of breath. She was 109/L), but it was stopped 3 days later because treated empirically for a possible pulmonary of mucositis. More than 30 years ago, the infection with a variety of antibiotics (ceftri- patient had been diagnosed with "pernicious Her platelet axone, ticarcillin-clavulanate, erythromycin, anemia.
  • Treatment of 51 Pregnancies with Danaparoid Because of Heparin

    Treatment of 51 Pregnancies with Danaparoid Because of Heparin

    ©2005 Schattauer GmbH,Stuttgart Blood Coagulation, Fibrinolysis and CellularHaemostasis Treatment of 51 pregnancies withdanaparoidbecause of heparin intolerance EdelgardLindhoff-Last1 ,Hans-Joachim Kreutzenbeck2 ,Harry N. Magnani3 1 Division ofVascular Medicine,Department of Internal Medicine,University Hospital Frankfurt, Germany 2 MedicalDepartment, Celltech, Essen, Germany 3 Clinical Consultant Marketing, OrganonBV, Oss,The Netherlands Summary Pregnant patients withacute venous thrombosis or ahistoryof required (3/14) or an adverse eventled to atreatment discon- thrombosis mayneed alternative anticoagulation, when heparin tinuation (11/14).Four maternal bleeding events were recorded intolerance occurs. Onlylimited dataonthe useofthe hepari- during pregnancy, deliveryorpostpartum, twoofthemwere noiddanaparoid areavailable in literature.We reviewedthe use fatal duetoplacental problems.Three fetal deathswererec- of danaparoid in 51 pregnancies of 49 patients identified in litera- orded,all associated with maternal complications antedating da- turebetween 1981 and 2004.All patients had developed hepa- naparoiduse.Danaparoid cross-reactivity was suspectedin4 rin intolerance (32 duetoheparin-induced thrombocytopenia, HITpatientsand 5non-HITpatientswith skin reactions and was 19 mainlydue to heparin-induced skin rashes)and had acurrent confirmedserologicallyinone of the twoHIT patients tested.In and/or pasthistoryofthromboembolic complications.The initial none of fivefetal cordblood- andthree maternal breast milk- danaparoid doseregimens ranged
  • Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory

    Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory

    Review Avoiding Intelligence Failures in the Cardiac Catheterization Laboratory: Strategies for the Safe and Rational Use of Dalteparin or Enoxaparin during Percutaneous Coronary Intervention Jonathan D. Marmur, MD, Renee P. Bullock-Palmer, MD, Shyam Poludasu, MD, Erdal Cavusoglu, MD ABSTRACT: Low-molecular-weight heparin (LMWH) has been a of unstable angina (UA) and non-ST-segment elevation myocardial mainstay for the management of acute coronary syndromes (ACS) for infarction (NSTEMI). The ESSENCE and TIMI 11B trials support almost a decade. However, several recent developments have seriously the use of LMWH over unfractionated heparin (UFH) in acute coro - threatened the prominence of this drug class: (i) the adoption of an nary syndromes managed with a predominantly medical approach early invasive strategy, frequently leading to percutaneous coronary in - 1,2 tervention (PCI) where the dosing and monitoring of LMWH is un - as opposed to an invasive initial strategy. familiar to most operators, (ii) the results of the SYNERGY trial, which Since the publication of the ESSENCE and TIMI 11B trials, not only failed to establish the superiority of enoxaparin over unfrac - the management of acute coronary syndromes (ACS) has tionated heparin with respect to efficacy, but also demonstrated more evolved to favor an early invasive strategy. This evolution is sup - bleeding with LMWH, and (iii) the results of the REPLACE-2 and ported by a number of studies, including the FRISC II and the ACUITY trials, which have demonstrated the advantages of an ACS TACTICS TIMI-18 trials. 3,4 The Superior Yield of the New and PCI treatment strategy based on direct thrombin inhibition with bivalirudin.
  • Heparin-Induced Thrombocytopenia (Hit)

    Heparin-Induced Thrombocytopenia (Hit)

    HEPARIN‐INDUCED THROMBOCYTOPENIA (HIT) OBJECTIVE: To assist clinicians with the diagnosis and initial management of heparin‐induced thrombocytopenia (HIT) and suspected HIT. BACKGROUND: HIT is a transient, immune‐mediated adverse drug reaction in patients recently exposed to heparin that generally produces thrombocytopenia and often results in venous and/or arterial thrombosis. HIT occurs in up to 5% of patients receiving unfractionated heparin (UFH) and in <1% who receive low molecular weight heparin (LMWH). HIT is characterised by immunoglobulin G (IgG) antibodies that recognize an antigen complex of platelet factor 4 (PF4) bound to heparin. These antibodies trigger a highly prothrombotic state by causing intravascular platelet aggregation, intense platelet, monocyte and endothelial cell activation and excessive thrombin generation. CLINICAL FEATURES: HIT typically presents with a fall in platelet count with or without venous and/or arterial thrombosis. Thrombocytopenia: A platelet count fall >30% beginning 5‐10 days after heparin exposure, in the absence of other causes of thrombocytopenia, should be considered to be HIT, unless proven otherwise. A more rapid onset of platelet count fall (often within 24 hours of heparin exposure) can occur when there is a history of heparin exposure within the preceding 3 months. Bleeding is very infrequent. Thrombosis: HIT is associated with a high risk (30‐50%) of new venous or arterial thromboembolism. Thrombosis may be the presenting clinical manifestation of HIT or can occur during or shortly after the thrombocytopenia. Other clinical manifestations of HIT: Less frequent manifestations include heparin‐induced skin lesions, adrenal hemorrhagic infarction, transient global amnesia, and acute systemic reactions (e.g. chills, dyspnea, cardiac or respiratory arrest following IV heparin bolus).
  • Low Molecular Weight Heparins and Heparinoids

    Low Molecular Weight Heparins and Heparinoids

    NEW DRUGS, OLD DRUGS NEW DRUGS, OLD DRUGS Low molecular weight heparins and heparinoids John W Eikelboom and Graeme J Hankey UNFRACTIONATED HEPARIN has been used in clinical ABSTRACT practice for more than 50 years and is established as an effective parenteral anticoagulant for the prevention and ■ Several low molecular weight (LMW) heparin treatment of various thrombotic disorders. However, low preparations, including dalteparin, enoxaparin and molecularThe Medical weight Journal (LMW) of heparinsAustralia haveISSN: recently 0025-729X emerged 7 October as nadroparin, as well as the heparinoid danaparoid sodium, more2002 convenient, 177 6 379-383 safe and effective alternatives to unfrac- are approved for use in Australia. 1 tionated©The heparin Medical (BoxJournal 1). of AustraliaIn Australia, 2002 wwwLMW.mja.com.au heparins are ■ LMW heparins are replacing unfractionated heparin for replacingNew Drugs,unfractionated Old Drugs heparin for preventing and treating the prevention and treatment of venous thromboembolism venous thromboembolism and for the initial treatment of and the treatment of non-ST-segment-elevation acute unstable acute coronary syndromes. The LMW heparinoid coronary syndromes. danaparoid sodium is widely used to treat immune heparin- ■ induced thrombocytopenia. The advantages of LMW heparins over unfractionated heparin include a longer half-life (allowing once-daily or twice-daily subcutaneous dosing), high bioavailability and Limitations of unfractionated heparin predictable anticoagulant response (avoiding the need
  • Guidelines for Administration of Anticoagulation for Patients Receiving Haemodialysis Lead Clinician

    Guidelines for Administration of Anticoagulation for Patients Receiving Haemodialysis Lead Clinician

    Guidelines for administration of Anticoagulation for patients receiving haemodialysis Lead Clinician: Dr. Diwaker Implementation date: January 2014 Last updated: April 2017 Last review date: May 2017 Planned review date: May 2019 Department: Renal Services SaTH Directorate: Medicine Hospital Site: SaTH Keywords: Tinzaparin, Heparin, anti-coagulant, HIT Comments: 1.0 INTRODUCTION The anticoagulant regime should be tailored to the needs of the individual patient, this includes the appropriate anticoagulant drug for the patients clinical condition. When blood comes into contact with the extra corporeal circuit, platelet adherence and activation of the intrinsic clotting cascade occurs, leading to thrombosis. Clots in the dialyser reduce the effective surface area of the dialyser and in extreme situations clots in the circuit may prevent treatment from continuing and result in loss of blood in the circuit. The aim is to anticoagulate the circuit without putting the patient at risk of bleeding. Fractionated heparin (Tinzaparin) is the recommended choice for stable patients on haemodialysis. Heparin is widely used for anticoagulation as the dose can be adjusted. It’s half-life is dramatically less than Tinzaparin. (30mins-2 hours rather than 4-5 hours) Indications for use of heparin would be the unwell CHD, AKI, uraemic patient. Heparin is the anti-coagulant of choice for those patients on Warfarin. We audit the loss of Haemodialysis circuits (ie when the dialysis lines are clotted and blood is lost to the patient). This audit trail shows that the majority of “Lost Circuits” occur when the patient is being dialysed “Heparin Free” or when the ACT guidelines have been misinterpreted.
  • Treatment of Acute Ischemic Stroke

    Treatment of Acute Ischemic Stroke

    The New England Journal of Medicine Drug Therapy The molecular events initiated by acute focal ische- mia can be summarized as a time-dependent cascade, characterized by decreased energy production; over- A LASTAIR J.J. WOOD, M.D., Editor stimulation of neuronal glutamate receptors (excito- toxicity); excessive intraneuronal accumulation of sodium, chloride, and calcium ions; mitochondrial in- TREATMENT OF ACUTE ISCHEMIC jury; and eventual cell death (Fig. 1).7, 1 4 -1 6 The funda- STROKE mental goals of intervention are to restore normal cer- ebral blood flow as soon as possible and to protect THOMAS BROTT, M.D., AND JULIEN BOGOUSSLAVSKY, M.D. neurons by interrupting or slowing the ischemic cas- cade.7, 1 4 , 1 5 Studies using magnetic resonance imaging (MRI) and positron-emission tomography suggest that critical ischemia rapidly produces a core of in- SCHEMIC stroke exacts a heavy toll in death and farcted brain tissue surrounded by hypoxic but po- disability worldwide. In the United States, where tentially salvageable tissue.8,17,18 Iit is the third leading cause of death and the lead- ing cause of serious long-term disability, approxi- EARLY EVALUATION AND SUPPORTIVE mately 750,000 strokes occur annually, with an an- TREATMENT nual mortality rate exceeding 150,000.1-4 Only about one third of patients who are having a In June 1996, the Food and Drug Administration stroke are aware of its symptoms, and most bystand- (FDA) approved tissue plasminogen activator (t-PA) ers are not knowledgeable about the signs of stroke. as a safe and effective treatment for stroke if it is giv- When symptoms or signs are recognized, emergency en within three hours after the onset of symptoms of medical services should be notified.19,20 Assessment stroke.5 Subsequently, results of large clinical trials should begin with evaluation of the patient’s airway, testing the efficacy of antiplatelet, antithrombotic, breathing, and circulation — the “ABCs” of resusci- and neuroprotective treatments appeared.
  • Danaparoid Sodium Lowers Proteinuria in Diabetic Nephropathy

    Danaparoid Sodium Lowers Proteinuria in Diabetic Nephropathy

    Danaparoid Sodium Lowers Proteinuria in Diabetic Nephropathy JOHAN W. VAN DER PIJL,* FOKKO J. VAN DER WOUDE,* PETRONELLA H. L. M. GEELHOEDDUIJVESTIJN,t MARIJKE FROLICH, FELIX J. M. VAN DER MEER, HERMAN H. P.J. LEMKES,” and LEENDERT A. VAN ES,* *Department of Nephrology, Leiden University Hospital, P0 Box 9600, 2300 RC Leiden, The Netherlands; tDepartment of Internal Medicine, Den Haag, The Netherlands; *Department of Clinical Chemistry, Leiden University Hospital, Leiden, The Netherlands; Department of Hematology, Leiden University Hospital, Leiden, The Netherlands; ‘Department of Endocrinology, Leiden University Hospital, Leiden, The Netherlands. Abstract. Diabetic nephropathy is a progressive renal disease sodium, the albumin excretion ratio standardized for urinary with thickening of the gbomerular basement membrane and creatinine reduced with 17% in comparison with an increase of mesangial expansion and proliferation as histological hall- 23% after placebo (95% confidence interval of the difference, marks. The presence of the glycosaminoglycan side chains of -75.9-3.9%; P = 0.03). The percentage change of the urinary heparan sulfate proteoglycan, an important constituent of the protein excretion corrected for urinary creatinine differed at 8 glomerular basement membrane, is decreased in diabetic ne- wk significantly between both treatment arms (P 0.001). phropathy proportionally to the degree of proteinuria. Danap- Additional parameters for safety as hematobogical, hemostasis, aroid sodium is a mixture of sulfated glycosaminoglycans biochemical parameters, and fundusphotography did not show consisting mainly of heparan sulfate. The study presented here any clinically significant difference for both groups. Only two involved performing a randomized placebo-controlled cross- patients had minor skin hematomas at the injection site while over study with danaparoid sodium in diabetic patients with using danaparoid sodium.
  • Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? an Analysis of Case Reports

    Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? an Analysis of Case Reports

    Magnani and Wester, 1:9 http://dx.doi.org/10.4172/scientificreports.423 Open Access Open Access Scientific Reports Scientific Reports Case Report OpenOpen Access Access Is Danaparoid Anticoagulation Suitable for Patients with HIT and ARF Requiring CVVRT? An Analysis of Case Reports Magnani HN1* and Wester JPJ2 1Clinical consultant, Oss, The Netherlands 2Department of Intensive Care Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands Abstract Purpose: To assess the efficacy and safety outcomes of case reports of danaparoid anticoagulation in critically ill ICU patients suffering from HIT who require CRRT. Method: A retrospective analysis of 103 cases. Results: Based on clinical signs, pre-treatment 4T scores and serological testing, HIT was reasonably ‘confirmed’ in 67.0% of the cases and ‘suspected’ in the remainder. The patients, with HIT and ARF received the danaparoid treatment regimen for CRRT for 1–39 (median 7) days. Dose adaptation was necessary in 40.2% of the patients to overcome thrombosis or bleeding (risk). Satisfactory CRRT anticoagulation was provided for 93.6% of 94 cases with information, 53.9% of the patients survived. The hospital mortality of 46.1% was mainly attributed to concomitant morbidity, but 5 deaths were related to thrombosis (n=2) or bleeding (n=3). Maintenance plasma anti-Xa activity correlated poorly with bleeding or thrombotic complications but positively with the minor bleeding frequency, hence advice to restrict the upper limit to 0.8 U/mL or preferably to use evidence of bleeding and systemic thrombosis/ circuit clotting to judge the need for dose adaptation. The benefit (no thrombosis)/harm (bleeding induction) ratio and combined inefficacy and major haemorrhagic frequency were 10.5 and 16.6% respectively, showing a generally favourable response to danaparoid.
  • Non-Interventional (Ni) Study Protocol

    Non-Interventional (Ni) Study Protocol

    Apixaban B0661069 NON-INTERVENTIONAL STUDY PROTOCOL Update 1, 08 January 2016 NON-INTERVENTIONAL (NI) STUDY PROTOCOL Post Author isation Safet y St udi es (PA SS) infor mation Title CARBOS – Comparative risk of major bleeding with new oral anticoagulants (NOACs) and Phenprocoumon in patients with atrial fibrillation: a retrospective claims database study in Germany Protocol number B0661069 Protocol version identifier Update 1.0 Date of last version of protocol 08 January 2016 EU Post Authorisation Study (PAS) ENCEPP/SDPP/11313 register number Active substance Apixaban (B01AF02) Phenprocoumon (B01AA04) Rivaroxaban (B01AX06; B01AF01) Dabigatran (B01AX06) Product reference EU/1/11/691/006 EU/1/11/691/007 EU/1/11/691/008 EU/1/11/691/009 EU/1/11/691/010 EU/1/11/691/011 Pfizer Confidential Page 1 of 112 Apixaban B0661069 NON-INTERVENTIONAL STUDY PROTOCOL Update 1, 08 January 2016 EU/1/11/691/012 EU/1/11/691/014 Procedure number Not Available Marketing Authorisation Holder (MAH) Pfizer Pharma GmbH Joint PASS No Research question and objectives The aim of this study is to investigate whether there are differences in the occurrence of major bleeding events in patients with NVAF and prescribed oral anticoagulation therapies in a real-world setting. It will be investigated whether the occurrence of major bleeding events in NVAF patients under anticoagulant therapy differs between patients treated with VKA (e.g. Phenprocoumon) and patients treated with Apixaban, Dabigatran or Rivaroxaban respectively. Country of study Germany Author Fabian Volz Pfizer
  • Heparin-Induced Thrombocytopenia1

    Heparin-Induced Thrombocytopenia1

    Heparin-Induced Thrombocytopenia1 Authors: Professor Andreas Greinacher2 and Doctor Norbert Lubenow Creation date: December 2003 Scientific Editor: Doctor Silvia Bellucci 1This review is based on a book chapter for the ETRO course 2003: Arnout J, de Gaetano G, Hoylaerts M, Peerlinck K, van Geet C, Verhaeghe R (Eds) Thrombosis: Fundamental and Clinical Aspects. Leuven University Press, 2003 2Ernst-Moritz-Arndt Universität, Institut für Immunologie und Transfusionsmedizin Klinikum, Sauerbruchstrasse, 17489 Greifswald, Germany. mailto:[email protected] Abstract Key words Definition Differential Diagnosis Pathogenesis Clinical Presentation Prognosis Laboratory Diagnosis Incidence Treatment Legal Aspects of HIT References Abstract Heparin-induced thrombocytopenia (HIT) is a relatively common immune-mediated disorder with the potential for serious thromboembolic complications. It is associated with the use of unfractionated heparin (UFH) and may be defined as a decrease in platelet count during or shortly after exposure to this anticoagulant. HIT occurs in up to 5% of patients who are exposed to UFH. Characteristic signs of HIT are a drop in platelet count of >50% and/or new thromboembolic complications during heparin therapy. Two types of HIT are recognized. Nonimmune heparin-associated thrombocytopenia is due to a direct interaction between heparin and platelets. The other type of HIT, immune-mediated HIT, is caused by heparin-dependent IgG (HIT-IgG) that recognizes a complex of heparin and platelet factor 4 (PF4), leading to platelet activation via the platelet Fc gammaRIIa receptor. Regular platelet count monitoring is best suited for early diagnosis of HIT, especially if UFH is used. Functional and antigen assays are available to confirm HIT. Heparin withdrawal and treatment with an agent that directly inhibits thrombin or decreases thrombin generation should be initiated prior to laboratory confirmation because of the rapidity with which thrombotic complications occur following platelet decline.